Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
CLEVELAND, April 10, 2017 -- Athersys, Inc. (Nasdaq:ATHX) will release its first quarter 2017 financial results at approximately 4:00 PM Eastern Time on Tuesday, May 9, 2017, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
| Date | May 9, 2017 | |
| Time | 4:30 p.m. (Eastern Time) | |
| Telephone access: US and Canada | (800) 273-1254 | |
| Telephone access: International | (973) 638-3440 | |
| Access code | 5869094 | |
| Live webcast | www.athersys.com under Investors section |
A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on May 23, 2017 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 5869094.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.
ATHX-G
Contact: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 [email protected] David Schull Russo Partners, LLC Tel: (212) 845-4271 or (858) 717-2310 [email protected] Investor Contact: Peter Vozzo Westwicke Partners (443) 213-0505 or (443) 377-4767 (mobile) [email protected]
